Cumberland VP granted 3,000 stock options at $2.80

Cumberland Pharmaceuticals vice president receives new stock options grant.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cumberland Pharmaceuticals vice president receives new stock options grant. Vice President of Organizational Development Anthony Todd M. was granted options to acquire 3,000 shares of Cumberland Pharmaceuticals common stock at an exercise price of $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 18, 2036. Following this award, his reported derivative holdings total 21,000 options.

Insider Trade Summary

Grant/Award: 3,000 shares

Grant/Award 1 txn

Insider Anthony Todd M.

Role Vice Pres Organizational Dev

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	3,000	$2.80	$8K

Holdings After Transaction: Options (right to buy) — 21,000 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cumberland Pharmaceuticals (CPIX) report in this Form 4?

The Form 4 reports a grant of stock options to a company vice president. He received options for 3,000 shares of common stock at an exercise price of $2.80 per share, reflecting a compensation-related award rather than an open-market trade.

Who is the insider in Cumberland Pharmaceuticals (CPIX) latest Form 4 filing?

The insider is Anthony Todd M., Vice President of Organizational Development at Cumberland Pharmaceuticals. He reported receiving a grant of options for 3,000 shares of common stock, bringing his reported derivative holdings to 21,000 options following this award.

What are the key terms of the 3,000 stock options granted at Cumberland Pharmaceuticals (CPIX)?

The options cover 3,000 shares of common stock with an exercise price of $2.80 per share. They become exercisable on March 18, 2030, carry an expiration date of March 18, 2036, and were reported as a grant or award acquisition.

Did the Cumberland Pharmaceuticals (CPIX) insider buy or sell shares on the market?

No open-market buying or selling occurred in this filing. The transaction is coded as a grant or award acquisition of options, giving the insider the right to buy 3,000 shares later at $2.80, rather than an immediate market trade.

How many derivative securities does the Cumberland Pharmaceuticals (CPIX) insider hold after this grant?

After the reported grant, the insider’s total derivative holdings are 21,000 options. This figure includes the newly awarded 3,000 options tied to Cumberland Pharmaceuticals common stock, as disclosed in the filing as the total following the transaction.

When do the newly granted Cumberland Pharmaceuticals (CPIX) options expire?

The granted options expire on March 18, 2036. They are first exercisable on March 18, 2030, giving the insider a multi-year window to purchase up to 3,000 shares at the fixed exercise price of $2.80 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/20/2026 - 05:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anthony Todd M.

(Last)

(First)

(Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE

TENNESSEE

37203

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Vice Pres Organizational Dev

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options (right to buy)	$2.8	03/18/2026		A		3,000		03/18/2030	03/18/2036	Common Stock	3,000	$2.8	21,000	D

Explanation of Responses:

Remarks:

	Todd M. Anthony by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR